News
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 15, 2021Industry leader brings relevant cell and gene therapy experience
-
Nov 4, 2021--Clinical data demonstrates ARU-1801 may be a safe and effective treatment for patients with severe sickle cell disease --
-
Oct 26, 2021-- Data to be presented shows improved survival out to 18 months in hypophosphatasia mice --
-
Oct 5, 2021Company to sponsor SCDAA 49th Annual National Convention to be held October 12 to 16, 2021
-
Sep 20, 2021-Data demonstrates promise for ARU-2801 as a potential one-time gene therapy treatment for hypophosphatasia-
-
Jun 28, 2021--Industry veteran CFO joins at critical juncture--
-
Jun 14, 2021--ARU-2801 is a potentially curative gene therapy in development for individuals with hypophosphatasia (HPP)--
-
May 27, 2021--Data demonstrates promise for lead program, ARU-1801, as potentially curative treatment for sickle cell disease--
-
May 12, 2021--Data suggest individualized melphalan dosing prior to ARU-1801 infusion may improve patient outcomes--
-
Apr 27, 2021--Data demonstrates treatment with ARU-1801 resulted in meaningful improvements in clinical outcomes for participants with severe sickle cell disease--
-
Dec 7, 2020--Data from improved manufacturing process resulted in significantly improved ARU-1801 product profile--
-
Nov 4, 2020--Ongoing manufacturing improvements shows enhanced efficacy of ARU-1801 for the treatment of sickle cell disease--
-
Jun 3, 2020
-
Jun 1, 2020--Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than 30 compounds including gene therapies for rare diseases--
-
May 11, 2020--Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell disease administered with reduced intensity conditioning--
-
Jan 22, 2020ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia
-
Jan 8, 2020ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia
-
Nov 19, 2019Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe and Asia
-
Dec 3, 2018Two patients have been administered RVT-1801 in conjunction with reduced intensity conditioning regimens